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Background
Each year breast cancer is diagnosed in approximately
1 million women worldwide [1]. Our lab has previously
linked Junctional Adhesion Molecule A (JAM-A) gene and
protein over-expression in breast tumours with an
increased risk of metastasis [2,3]. JAM-A loss or inhibition
has also been shown to inhibit cell migration and invasion
[2], while increasing apoptosis possibly as a result of
increased HER2 degradation and downstream Akt signal-
ling [3]. A novel JAM-A inhibitor was designed by our lab
which has been found to reduce the migration and prolif-
eration of 4T1 breast cancer cells in vitro, and reduce 4T1
tumour growth in vivo. In this study we sought to deter-
mine both the stability and the efficacy of the JAM-A inhi-
bitor on cell proliferation and cell signalling.
Methods
Cell proliferation was assessed in 4T1 and MCF7-HER2
breast cancer cell lines using the CyQUANT Proliferation
Assay. In parallel, changes in the expression and activity of
the HER2, ERa and Akt signalling pathways were assessed
by western blotting.
Results & discussion
There was no significant change in cell proliferation
between JAM-A inhibitor treated and control treated
cells and there was no significant difference in effect
between the different JAM-A inhibitor concentrations.
This suggests that the JAM-A inhibitor is not stable
enough to be stored long-term at -80°C, as it had been
prior to the commencement of this study. This conclu-
sion was further supported by western blots showing no
significant changes in the expression or activity of HER2,
ERa and Akt following treatment with the JAM-A
inhibitor.
Conclusion
The JAM-A inhibitor did not inhibit cell proliferation
and had no effect on cell signalling pathways downstream
of JAM-A. This highlights the importance of further
experiments to determine the precise shelf-life of the
inhibitor, and additional chemical alterations may be
necessary to increase the stability of the compound.
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